Asceneuron Appoints Peter Van Vlasselaer as Chairman
Serialbiotechentrepreneurjoinsleading small molecule tau modulationcompany
Asceneuron, an emerging leader in the development of orally bioavailable modulators of tau pathology for the treatment of neurodegenerative diseases, today announces the appointment of Peter Van Vlasselaer as Chair of the Board of Directors.
Peter Van Vlasselaer, PhD has over 20 years executive and entrepreneurial experience in the biotech industry. He was most recently the Founder, Preside...